NASDAQ:ALLR • US0167445008
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ALLARITY THERAPEUTICS INC (ALLR).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-10 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-12-09 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-09-26 | Ascendiant Capital | Maintains | Buy -> Buy |
| 2025-07-28 | Ascendiant Capital | Initiate | Buy |
| 2022-08-23 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2022-05-27 | Ladenburg Thalmann | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 320K | -100.00% | 8.758M | |||
| EBITDA YoY % growth | -17.092M -1.54% | -17.529M -2.56% | N/A | N/A | N/A | |
| EBIT YoY % growth | -17.129M -1.40% | -17.538M -2.39% | -12.605M 28.13% | -15.912M -26.24% | -16.64M -4.58% | |
| Operating Margin | N/A | N/A | -3,939.06% | N/A | -190.00% | |
| EPS YoY % growth | -123,690.00 93.35% | N/A 99.94% | N/A 98.99% | -0.99 -22.78% | -25.70 -2,497.94% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.24 | -0.24 -63.20% | -0.24 -28.84% | -0.24 -9.09% |
| Revenue Q2Q % growth | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.978M -31.03% | -3.978M 3.75% | -3.978M -57.98% | -3.978M -36.33% |
All data in USD
7 analysts have analysed ALLR and the average price target is 9.69 USD. This implies a price increase of 714.29% is expected in the next year compared to the current price of 1.19.
ALLARITY THERAPEUTICS INC (ALLR) will report earnings on 2026-05-09.
The consensus EPS estimate for the next earnings of ALLARITY THERAPEUTICS INC (ALLR) is -0.24 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering ALLARITY THERAPEUTICS INC (ALLR) is 7.